Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

Argirović, A.; Argirovic, D.

doi:10.2298/vsp110620029a

Cited by 20 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When saw palmetto was compared with effective medicine remedies like 5-alpha-reductase inhibitors, finasteride intake reduced PSA concentrations, whereas Serenoa repens ONS failed to induce any changes [ 127 ]. Similarly, compared with tamsulosin [ 125 , 128 , 129 ], saw palmetto did not have a significant effect on PSA concentrations after 6 [ 128 ] and 12 [ 130 ] months of supplementation. Moreover, according to a recent Chinese meta-analysis [ 131 ], saw palmetto was more effective in reducing PSA concentrations among men with BPH as compared with tamsulosin; however, in this analysis, non-randomized trials were analyzed together with RCTs.…”

Section: Antioxidants and Psa Kineticsmentioning

confidence: 99%

Dietary Factors and Supplements Influencing Prostate-Specific Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials

et al. 2020

View full text Add to dashboard Cite

The quest for dietary patterns and supplements efficient in down-regulating prostate-specific antigen (PSA) concentrations among men with prostate cancer (PCa) or increased PCa risk has been long. Several antioxidants, including lycopene, selenium, curcumin, coenzyme Q10, phytoestrogens (including isoflavones and flavonoids), green tea catechins, cernitin, vitamins (C, E, D) and multivitamins, medicinal mushrooms (Ganoderma lucidum), fruit extracts (saw palmetto, cranberries, pomegranate), walnuts and fatty acids, as well as combined supplementations of all, have been examined in randomized controlled trials (RCTs) in humans, on the primary, secondary, and tertiary PCa prevention level. Despite the plethora of trials and the variety of examined interventions, the evidence supporting the efficacy of most dietary factors appears inadequate to recommend their use.

show abstract

Section: Antioxidants and Psa Kineticsmentioning

confidence: 99%

Dietary Factors and Supplements Influencing Prostate-Specific Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The clinical responses to phytotherapy with Serenoa repens extracts are found to be very promising in other studies, too [21,22]. Some authors describes the improvement in erectile function and decreasing complications following transurethral resection of the prostate, especially bleeding [23].…”

Section: Discussionmentioning

confidence: 99%

Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia

Saidi

Stavridis

Stankov

et al. 2017

Prilozi

View full text Add to dashboard Cite

An increasing tendency has recently emerged for the use of phytotherapeutic agents as alternative to commercial pharmacological agents for the treatment of benign prostate hyperplasia (BPH). The purpose of this study is to evaluate the effects of Serenoa repens alcohol extract treatment on BPH patients' symptoms and major parameters during one-year follow-up. The study was performed on 70 men aged 40 -79 years (mean 60.58) with symptomatic BPH that were divided into a group of 40 patients treated with Serenoa repens extract (SRT) and a control group of 30 patients that received no treatment and were observed only. The following parameters were determined at the time of diagnosis (baseline), and after 6 and 12 months: prostate size, serum prostate-specific antigen (PSA) and uroflowmetry parameters including maximum flow rate (MFR), average flow rate (AFR) and post-voiding residual volume (PVRV). In addition, the relevant patient symptoms were evaluated using the International Prostate Symptom Score (IPSS) system. The patients in the SRT group showed a statistically significant increment of the average MFR and AFR values and reduction of PV relative to the control group (p<0.05). The significant differences between the proportion of patients with prostate volume >40 ml in the SRE treated group vs. control group was observed (p<0.05). The mean IPSS score was highly significantly reduced in the SRT group (p<0.01). The mild improvements of the urine flow, prostate size and IPSS score during 12 months treatment with the Serenoa repens extract indicate possible efficiency of this phytotherapeutic agent in patients with BPH.

show abstract

“…Twenty-three studies were excluded for lack of useful data. Thus four articles reporting data from four RCTs (Argirovic & Argirovic, 2013;Debruyne et al, 2002;Kaplan, 2016;Morgia et al, 2015) that compared Serenoa repens with tamsulosin over 24-week treatment cycle were included in the analysis (Figure 1). Table 1 presents the baseline characteristics of studies.…”

Section: Characteristics Of the Individual Studiesmentioning

confidence: 99%

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis

Cai

Cui

et al. 2020

Am J Mens Health

View full text Add to dashboard Cite

Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms (LUTS). This article carried out a systematic review and meta-analysis to compare Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia (BPH) after at least 6-month treatment cycle. Four studies involving 1,080 patients (543 in the Serenoa repens group and 537 in the tamsulosin group) were included in the meta-analysis. The results were as follows: compared with tamsulosin, Serenoa repens had a same effect in treating BPH in terms of International Prostate Symptom Score (IPSS) (mean difference [MD] 0.63, 95% confidence interval [CI] [−0.33, 1.59], p = 0.20), quality of life (QoL) (MD 1.51, 95% CI [−1.51, 4.52], p = 0.33), maximum flow rate (Qmax) (MD 0.27, 95% CI [−0.15, 0.68], p = 0.21), postvoid residual volume (PVR) (MD −4.23, 95% CI [−22.97, 14.44], p = 0.65), prostate-specific antigen (PSA) (MD 0.46, 95% CI [−0.06, 0.97], p = 0.08) with the exception of prostate volume (PV) (MD −0.29, 95% CI [−0.41, −0.17], p < 0.00001). For side effects, Serenoa repens was well tolerated compared with tamsulosin especially in ejaculation disorders (odds ratio [OR] = 12.56, 95% CI [3.83, 41.18], p < 0.0001) and decreased libido (OR = 5.40; 95% CI [1.17, 24.87]; p = 0.03). This study indicated that Serenoa repens had the same effect in treating BPH compared with tamsulosin in terms of IPSS, QoL, and PVR after at least 6-month treatment cycle, however, the latter had a greater improvement in PV compared with the former. And Serenoa repens did not increase the risk of adverse events especially with respect to ejaculation disorders and libido decrease.

show abstract

Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

Cited by 20 publications

References 13 publications

Dietary Factors and Supplements Influencing Prostate-Specific Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials

Dietary Factors and Supplements Influencing Prostate-Specific Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials

Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About